Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Richard Stone

Showing results (511-520 of 544) with videos related to

Pageof 55
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 2, 2011
Implementing a geriatric assessment in cooperative group clinical cancer trials: CALGB 360401Arti Hurria, Constance T Cirrincione, Hyman B Muss, et al.
Nature Cell Biology|November 8, 2016
Lgr6 labels a rare population of mammary gland progenitor cells that are able to originate luminal mammary tumoursLeander Blaas, Fabio Pucci, Hendrik A Messal, et al.
Molecular Therapy. Oncology|April 15, 2025
Erratum: Dual CARM1-and IKZF3-targeting: A novel approach to multiple myeloma therapyWei Ni, Swati Garg, Basudev Chowdhury, et al.
Blood|May 5, 2017
Selective inhibition of nuclear export with selinexor in patients with non-Hodgkin lymphomaJohn Kuruvilla, Michael Savona, Rachid Baz, et al.
Blood|March 25, 2017
A phase 1 clinical trial of single-agent selinexor in acute myeloid leukemiaRamiro Garzon, Michael Savona, Rachid Baz, et al.
Journal of Veterinary Internal Medicine|October 5, 2020
Lyophilized platelets versus cryopreserved platelets for management of bleeding in thrombocytopenic dogs: A multicenter randomized clinical trialRobert Goggs, Benjamin M Brainard, Dana N LeVine, et al.
Blood Advances|September 28, 2021
PD-1 inhibition in advanced myeloproliferative neoplasmsGabriela Hobbs, Cansu Cimen Bozkus, Erin Moshier, et al.
Leukemia|July 30, 2021
Small molecule inhibition of deubiquitinating enzyme JOSD1 as a novel targeted therapy for leukemias with mutant JAK2Jing Yang, Ellen L Weisberg, Xiaoxi Liu, et al.
Blood|September 30, 2008
Antileukemic effects of the novel, mutant FLT3 inhibitor NVP-AST487: effects on PKC412-sensitive and -resistant FLT3-expressing cellsEllen Weisberg, Johannes Roesel, Guido Bold, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 29, 2013
A genome-wide aberrant RNA splicing in patients with acute myeloid leukemia identifies novel potential disease markers and therapeutic targetsSophia Adamia, Benjamin Haibe-Kains, Patrick M Pilarski, et al.
Pageof 55

Showing results (511-520 of 544) with videos related to

Sort By:
Pageof 55
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 2, 2011
Implementing a geriatric assessment in cooperative group clinical cancer trials: CALGB 360401Arti Hurria, Constance T Cirrincione, Hyman B Muss, et al.
Nature Cell Biology|November 8, 2016
Lgr6 labels a rare population of mammary gland progenitor cells that are able to originate luminal mammary tumoursLeander Blaas, Fabio Pucci, Hendrik A Messal, et al.
Molecular Therapy. Oncology|April 15, 2025
Erratum: Dual CARM1-and IKZF3-targeting: A novel approach to multiple myeloma therapyWei Ni, Swati Garg, Basudev Chowdhury, et al.
Blood|May 5, 2017
Selective inhibition of nuclear export with selinexor in patients with non-Hodgkin lymphomaJohn Kuruvilla, Michael Savona, Rachid Baz, et al.
Blood|March 25, 2017
A phase 1 clinical trial of single-agent selinexor in acute myeloid leukemiaRamiro Garzon, Michael Savona, Rachid Baz, et al.
Journal of Veterinary Internal Medicine|October 5, 2020
Lyophilized platelets versus cryopreserved platelets for management of bleeding in thrombocytopenic dogs: A multicenter randomized clinical trialRobert Goggs, Benjamin M Brainard, Dana N LeVine, et al.
Blood Advances|September 28, 2021
PD-1 inhibition in advanced myeloproliferative neoplasmsGabriela Hobbs, Cansu Cimen Bozkus, Erin Moshier, et al.
Leukemia|July 30, 2021
Small molecule inhibition of deubiquitinating enzyme JOSD1 as a novel targeted therapy for leukemias with mutant JAK2Jing Yang, Ellen L Weisberg, Xiaoxi Liu, et al.
Blood|September 30, 2008
Antileukemic effects of the novel, mutant FLT3 inhibitor NVP-AST487: effects on PKC412-sensitive and -resistant FLT3-expressing cellsEllen Weisberg, Johannes Roesel, Guido Bold, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 29, 2013
A genome-wide aberrant RNA splicing in patients with acute myeloid leukemia identifies novel potential disease markers and therapeutic targetsSophia Adamia, Benjamin Haibe-Kains, Patrick M Pilarski, et al.
Pageof 55